X-GEN Pharmaceuticals may be a young company, but its management has decades of experience in the pharmaceutical industry. The management team offers a fresh approach, deeply rooted in tradition, which has prepared the company for significant growth in the coming years. Established in 2003 and based in Long Island, New York, the privately-owned family company remains committed to the long-standing vision of founder Dan Badia, whose strategic focus was centered on building a lineup of drug products long past patent expiration, but essential to the health care community. The new management team, led by president and chief executive officer Susan Badia, has added an important twist—a greater commitment to broadening its product portfolio. With a strong product line composed of 50 National Drug Codes, X-GEN is positioned to expand its product focus.“We still search out products that are low volume, with few competitors, which have been off patent for
"The strong relationships we have throughout the supply chain allow us to maximize market share and logistical efficiencies. Additionally, our size, organizational structure and focused strategies allow us to respond quickly to an ever-changing market place.”
Catherine Liles, Corporate Treasurer Susan Badia, President and CEO J. Robin Liles, Corporate Vice President
“We’re committed to developing a broader line of products,” says J. Robin Liles, Corporate Vice President. “We select products based on our ability to effectively enhance patient care through the delivery of an affordable generic equivalent.” Although the company’s typical approach to product development is to file and own Abbreviated New Drug Applications, the strategy of X-GEN incorporates portfolio expansion through the structuring of partnerships which allow the company to leverage its own core competencies as well as those of its partners. “X-GEN has alliances with both US and overseas companies, through licensing and marketing agreements, which capitalize on existing supply chain expertise and facilitate rapid channeling of new products,” Liles said. “Ultimately, the goal is to add 3 to 5 products a year to the company portfolio, with a projection of 12 to 15 products within the next 3 years.”
several years,” said Rob Liles, corporate vice president. “We will continue to add those types of products, but now we also look at drugs nearing patent expiration which open those markets to generic competition. Our experience, partnerships, and resources ready us to thrive in those product markets".